projects
We currently support several projects working with world reknowned scientists and biotechs to enable and accelerate drug discovery in CBD. Our collaborators are found spread all over the world.
Karolinska Institute (KI), Stockholm, Sweden
Per Svenningsson, Hans Grönlund, Lars Farde
University College London (UCL), London, UK
Tom Warner, Tamas Revezs, Helen Ling, Janice Holton, John Hardy, Nick Wood, Huw Morris
The Feinstein Institute for Medical Research, New York, USA
Peter Davies
Mayo Clinic, Jacksonville, USA
Naomi Kouri, Dennis Dickson
National Institute of Radiological Science (NIRS), Chiba, Japan
Makoto Higuchi, Tetsuya Suhara
UCSF, San Francisco, USA
Adam Boxer
curePSP, USA
NSgene, Providence, USA
C2N Diagnostics, Saint Louis, USA
Cortice Bioscience, New York, USA
Alzecure Foundation, Stockholm, Sweden
Tau Consortium, USA
Research projects funded by CBD Solutions focus on:
Stem Cell Models (iPSc) - UCL
Skin cells (fibroblast), from patients with taupathies, is used to develop (Induced pluripotent stem cells) cellular models that better replicate the disease.
Genetics – UCL, UPenn, Mayo Clinic
Through GWAS and exome sequencing of pathological confirmed CBD patients DNA, we identify new genes that may increase risk for CBD.
Pathology - UCL
By studying brains - donated by CBD patients, we map spreading and identify new disease mechanisms.
Animal Models - KI
New and better animal models are developed to test disease mechanism and drugs
Biomarkers - KI
Identification of biomarkers will improve diagnosis accuracy and enable quantification of disease progression
CBD patient cohorts - UCL
CBD patient cohorts is being constructed to facilitate future clinical studies and clinical trials of potential therapies
Brain delivery - NSgene
A new technology, using encapsulated cells biodelivery, is developed to facilitate antibody delivery into the brain
Scales - UCSF
New scales are being developed to facilitate quantification of disease progression and effects of future therapies
Tau antibodies – C2N Diagnostic
Development of Tau antibodies with therapeutic potential in CBD. The hypothesis that these antibodies will bind toxic tau and block disease spreading in the brain
PET tau imaging – NIRS, KI
Radio labeled ligands that specifically bind tau are evaluated -- using positron emission tomography (PET) to visualize pathological tau aggregates in the living brain of CBD patients
Clinical trials – UCSF, Cortice Bioscience
Safety study of TPI-287 to treat CBD and PSP
